Contact
 

Speaking at a media briefing in Cape Town, Dr. Zeda Rosenberg, CEO of the International Partnership for Microbicides, described results of the CAPRISA microbicide trial as a “huge achievement,” but emphasized that the candidate gel needs to be...

Alan Bernstein and Peter Piot
The Globe and Mail (Canada)
Tuesday, August 10 2010

...

The Enterprise hosted and participated in a handful of activities at AIDS 2010.  A summary of the meeting is posted below.

The New York Times reported on the CAPRISA 004 results in an article today, “Advance on AIDS Raises Questions as Well as Joy.” The story notes that “after more than a dozen microbicide failures, [the results were] a huge relief, and led to...

The International AIDS Vaccine Initiative (IAVI) issued a statement on advances on HIV prevention tools at the International AIDS Conference in Vienna.  The full statement is below.

The Honourable Leona Aglukkaq, Minister of Health in collaboration with the Bill & Melinda Gates Foundation, announced the renewed Canadian HIV Vaccine Initiative (CHVI), which features the creation of the CHVI Research and Development...

The National Institute of Allergy and Infectious Diseases National Institutes of Health congratulate the Centre for the AIDS Program

WHO and UNAIDS congratulate CAPRISA, a designated UNAIDS Collaborating Centre for HIV Prevention Research, on the successful completion of the study.  The full statement is available here:...

The HIV Vaccine Trials Network (HVTN) issued a statement on the CAPRISA 004 microbicide trial.  The full statement is below.

The Centre for the AIDS Programme of Research in South Africa (CAPRISA) reports that researchers have achieved an important scientific breakthrough in the fight against HIV and genital herpes with a vaginal gel that significantly reduces a woman'...

Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account